Is acid phosphatase (PAP) still justified in the management of prostatic cancer?

Related Experiment Videos

¹Department of Surgery, Oulu University Central Hospital, Finland.

Acta Oncologica (Stockholm, Sweden)

|January 1, 1991

Abstract:

The usefulness of acid phosphatase (PAP) and prostate specific antigen (PSA) is compared. The author concludes that PSA is more sensitive, has better organ specificity, does less diurnal variations and correlates better with tumor which makes PSA superior for staging and monitoring of therapy in prostate cancer.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

[Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study.].

Laeknabladid·2010

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

British journal of urology·1997

Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethylstilbestrol. A double-blind study. The SPCG-1 Study Group. Scandinavian Prostate Cancer Group.

Scandinavian journal of urology and nephrology·1997

Antibiotic prophylaxis in patients with urinary retention undergoing transurethral prostatectomy.

Annales chirurgiae et gynaecologiae·1997

[Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·1996

[Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].

Ugeskrift for laeger·1996

See all related articles